Haplotype Labs provides a SaaS platform that enables genetic testing labs, medical practices, and clinical trials to predict, detect, and prevent diseases using polygenic risk models. The platform also reduces sequencing costs and streamlines research workflows.

Mike Polcari's 15 years at 23andMe, culminating in his role as Chief Architect building their genetic testing models, provides him with unparalleled expertise and a proven track record in the field. His direct experience and the genesis of Haplotype Labs' idea during his tenure at 23andMe position him as a highly credible and capable leader. The company is poised to capitalize on several strong tailwinds, including the Cures Act 2.0 enabling access to immediate clinical and claims data, increasing payer proactiveness in risk assessment and stratification, and big pharma's growing appetite for better health forecasts to avoid clinical trial delays. These external factors create a fertile ground for Haplotype Labs' growth and adoption. Haplotype Labs aims to build a new polygenic risk model that goes beyond current limitations by incorporating a patient's DNA and gene data with historical clinical, claims, medication, diagnoses, and summary of care data. This comprehensive approach promises a more accurate and valuable product than the existing status quo, offering a 10x experience for early adopters like concierge medical practices, with a clear path to scale through payers and providers.